As medicine advances, scientists are constantly improving monoclonal antibodies to make them more effective. One such modification is afucosylation, which removes fucose sugar residues from the fragment crystallizable (Fc) region. This change significantly boosts the immune system’s ability to recognize and destroy harmful cells, making afucosylated antibodies a powerful tool in treating cancer, autoimmune diseases, and infectious diseases.
Afucosylated antibodies are monoclonal antibodies that lack fucose sugar residues on their Fc region. This modification improves their ability to bind to immune cell receptors, enhancing antibody-dependent cellular cytotoxicity (ADCC). As a result, these antibodies are widely used in the treatment of cancer, autoimmune diseases, and inflammatory conditions.
The removal of fucose from the Fc region strengthens the interaction between antibodies and Fc Gamma Receptors on natural killer (NK) cells. This leads to:
Increased immune activation, enabling natural killer cells to recognize and attack target cells more effectively.
Improved cell destruction, making these antibodies more efficient in eliminating harmful cells.
Broader therapeutic applications, particularly in cancer and immune-related diseases.
Stimulation of peripheral blood mononuclear cells, enhancing overall immune response.
Stronger engagement with IgG1 Fc domains, optimizing therapeutic function.
Afucosylated antibodies are characterized by the absence of fucose sugar residues on their Fc (fragment crystallizable) region. This modification has major implications for the antibody's functionality, particularly in enhancing antibody-dependent cellular cytotoxicity (ADCC).
The primary mechanism of action of afucosylated antibodies is through enhanced ADCC. ADCC is a critical immune response where immune cells, such as natural killer (NK) cells, recognize and lyse target cells coated with antibodies. The effectiveness of ADCC largely depends on the interaction between the Fc region of the antibody and the Fcγ receptor IIIa (FcγRIIIa) on NK cells. Afucosylated antibodies exhibit increased binding affinity to FcγRIIIa due to the absence of core fucose residues, which otherwise sterically hinder this interaction in fucosylated antibodies.
Several studies have demonstrated the enhanced binding affinity of afucosylated antibodies. For instance, Shields et al. (2002) showed that removing the fucose from the Fc region increased binding affinity to FcγRIIIa by up to 50-fold, leading to significantly improved ADCC activity. This stronger binding likely leads to a more stable interaction and cross-linking between the Fc region and FcγRIIIa, directly influencing NK cell activation and subsequent target cell lysis.1
Additionally, the structural basis for this improved interaction has been characterized using crystallography. Ferrara et al. (2011) provided a detailed structural analysis, revealing that the absence of fucose alters the conformation of the Fc region, facilitating closer and more stable interactions with FcγRIIIa.2 This structural adaptation is crucial for the superior therapeutic efficacy observed in afucosylated antibodies.
The enhanced ADCC activity has therapeutic implications, particularly in oncology and autoimmune diseases. Several therapeutic antibodies have been developed and are currently in clinical use or undergoing clinical trials. One notable example is obinutuzumab (GA101), an afucosylated anti-CD20 monoclonal antibody used in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL) and follicular lymphoma. Obinutuzumab has demonstrated superior efficacy compared to rituximab, a fucosylated anti-CD20 antibody, due to its enhanced ADCC activity. A pivotal phase III study reported significantly improved progression-free survival in patients treated with obinutuzumab compared to those receiving rituximab.3,4
Another promising application is in the treatment of autoimmune diseases. For example, inebilizumab (MEDI-551) an afucosylated anti-CD19 antibody has shown potential in treating patients with relapsing forms of multiple sclerosis. It is a humanized IgG1κ monoclonal antibody which binds to and depletes CD19+ B cells. A Phase 1 study in 2017 showed inebilizumab had an acceptable safety profile with a trend in reductions in new/newly enlarging and gadolinium-enhancing lesions.5
Furthermore, advances in glycoengineering have enabled the production of afucosylated antibodies with tailored glycosylation profiles to maximize their therapeutic potential. Techniques such as glycosylation pathway engineering in CHO (Chinese hamster ovary) cells have been instrumental in this regard, ensuring consistent and high-yield production of afucosylated antibodies.6
Advancements in glycoengineering have allowed for more efficient production of afucosylated antibodies by precisely modifying their glycosylation patterns. One of the key innovations involves engineering CHO (Chinese hamster ovary) cells to prevent the attachment of fucose residues, ensuring the consistent production of afucosylated antibodies. Additionally, researchers have refined glycosylation techniques to enhance antibody stability, binding efficiency, and overall therapeutic function, making these modifications more effective for clinical applications.
At Biointron, we have developed the CHOK1BN-Fut8KO expression platform, optimized for afucosylated antibody production. This innovation:
Removes the Fut8 enzyme, preventing unwanted fucose residue attachment to the cell surface.
Offers a scalable, cost-efficient solution for manufacturing next-generation therapeutics.
Facilitates the production of Afucosylated Anti-Cancer Antibodies, improving treatment outcomes.
Enables the development of afucosylated IgG1 antibodies for a range of therapeutic applications.
Supports the creation of Afucosylated anti-CD20 antibody, enhancing immune cell targeting.
Ensures strong IgG1 Fc interactions, optimizing antibody function.
To learn more about antibody modifications and glycoengineering, explore:
Afucosylated antibodies have emerged as a critical advancement in therapeutic antibody development, significantly enhancing immune response mechanisms. Their ability to improve antibody-dependent cellular cytotoxicity (ADCC) by strengthening interactions with immune cells makes them valuable in treating cancer, autoimmune diseases, and inflammatory disorders. By modifying glycosylation patterns, these antibodies optimize immune engagement, leading to more effective and targeted therapies. Discover how Biointron’s advanced antibody solutions can support your therapeutic goals. Contact us today to learn more!
Looking to optimize your antibody production with advanced afucosylation technology? Contact Biointron today to explore tailored solutions for your research and therapeutic applications.
Shields, R. L., Lai, J., Keck, R., O’Connell, L. Y., Hong, K., Meng, Y. G., ... & Presta, L. G. (2002). Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. Journal of Biological Chemistry, 277(30), 26733-26740.
Ferrara, C., Grau, S., Jäger, C., Sondermann, P., Brünker, P., Waldhauer, I., ... & Umaña, P. (2011). Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose. Proceedings of the National Academy of Sciences, 108(31), 12669-12674.
Alduaij, W., Ivanov, A., Honeychurch, J., Cheadle, E. J., Potluri, S., Lim, S. H., ... & Cragg, M. S. (2011). Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood, 117(17), 4519-4529.
Townsend, W., Hiddemann, W., Buske, C., Cartron, G., Cunningham, D., Dyer, J. S., Gribben, J. G., Phillips, E. H., Dreyling, M., Seymour, J. F., Grigg, A., Trotman, J., Lin, Y., Hong, N., Kingbiel, D., Nielsen, T. G., Knapp, A., Herold, M., & Marcus, R. (2023). Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study. HemaSphere, 7(7). https://journals.lww.com/hemasphere/fulltext/2023/07000/obinutuzumab_versus_rituximab_immunochemotherapy.9.aspx
Agius, M. A., Klodowska-Duda, G., Maciejowski, M., Potemkowski, A., Li, J., Patra, K., Wesley, J., Madani, S., Barron, G., Katz, E., & Flor, A. (2017). Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Multiple Sclerosis Journal. https://journals.sagepub.com/doi/10.1177/1352458517740641
Yang, Z., Wang, S., Halim, A., Schulz, M. A., Frodin, M., Rahman, S. H., B, M., Behrens, C., Kristensen, C., Vakhrushev, S. Y., Bennett, E. P., Wandall, H. H., & Clausen, H. (2015). Engineered CHO cells for production of diverse, homogeneous glycoproteins. Nature Biotechnology, 33(8), 842-844. https://www.nature.com/articles/nbt.3280
PEGS Europe2025 conference was held inLisbon, Portugal, fromNovember11to Novembe……
Antibody discovery has traditionally relied on selecting clones based on target ……
The Society for Immunotherapy of Cancer (SITC) 2025 conference was held in Natio……
A VHH library is a collection of variable domains of heavy-chain antibodies (VHH……
You can also contact us on the Scientist and Science Exchange marketplaces.
